Chhabra Arvind, Mukherji Bijay
Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States.
Department of Medicine, University of Connecticut Health Center, Farmington, CT, United States.
Hum Immunol. 2016 Oct;77(10):905-911. doi: 10.1016/j.humimm.2016.06.011. Epub 2016 Jun 16.
Regulatory T cells (Treg) can interfere with the generation and function of anti-tumor immune effectors. Accordingly, ways that could block Treg function would be useful in cancer immunotherapy. We have previously shown that incorporation of CD4+CD25-ve T cells in an in vitro cytolytic T lymphocyte (CTL) generation assay leads to generation of induced regulatory T cells (iTregs), and that these iTreg block the generation of productive CTL response (Chattopadhyay et al., 2006). We here show that human CD4 T cells engineered to express MHC class I-restricted human melanoma associated epitope, MART-127-35, specific T cell receptor (TCR), that can simultaneously exhibit helper as well as cytolytic effector functions (Chhabra et al., 2008, Ray et al., 2010), can interfere with the generation of inducible Treg, block iTreg-mediated suppression, and allow the activation and expansion of MART-127-35 specific CTL responses, in vitro. We also show that mitigation of Treg generation by TCR engineered CD4 T cells is not mediated by a soluble factor and may involve "licensing/conditioning" of the dendritic cells (DC). Our data offer novel insights on the biology of MHC class I restricted TCReng CD4 T cells and have translational implications.
调节性T细胞(Treg)可干扰抗肿瘤免疫效应细胞的产生和功能。因此,能够阻断Treg功能的方法在癌症免疫治疗中会很有用。我们之前已经表明,在体外细胞毒性T淋巴细胞(CTL)生成试验中加入CD4+CD25阴性T细胞会导致诱导调节性T细胞(iTregs)的产生,并且这些iTreg会阻断有效的CTL反应的产生(Chattopadhyay等人,2006年)。我们在此表明,经过基因工程改造以表达MHC I类限制性人黑色素瘤相关表位MART-127-35、特异性T细胞受体(TCR)的人CD4 T细胞,能够同时展现辅助以及细胞毒性效应功能(Chhabra等人,2008年,Ray等人,2010年),在体外可干扰诱导性Treg的产生,阻断iTreg介导的抑制作用,并使MART-127-35特异性CTL反应得以激活和扩增。我们还表明,经TCR工程改造的CD4 T细胞减轻Treg产生并非由可溶性因子介导,可能涉及树突状细胞(DC)的“许可/预处理”。我们的数据为MHC I类限制性TCR工程化CD4 T细胞的生物学特性提供了新见解,并具有转化意义。